Abstract
Introduction: A-HeFT established the benefit of ISDN/HYD as adjunctive therapy for HF when added to evidence-based agents in AA patients with NYHA class III/IV HF. Objective: X-A-HeFT tested the continued safety and tolerability of ISDN/HYD. Methods: A total of 198 AA A-HeFT patients were treated with ISDN/HYD in addition to standard therapy for HF. Patient characteristics (mean +/− SD): age- 57.4 +/− 12.7 yrs; gender M:F (%) 58:42; wgt- 97.6 +/− 27.4 kg. Medical history: HTN 93.9%, duration 12.6 +/− 11.7 yrs; DM- 40.9%; CRI- 13.6%; Prior MI- 29.3%.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call